Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pfizer Considers Deal With Icagen
by Ann M. Thayer
July 4, 2011
| A version of this story appeared in
Volume 89, Issue 27
Pfizer is evaluating the possibility of extending or amending its collaborative relationship with Icagen or increasing its ownership stake in the smaller firm. R&D partners since 2007, the two companies have already twice extended their agreement, which expires in December. In the past four years, Pfizer has spent $15 million to buy about 1.1 million shares of Icagen stock, or about 15% of the company’s outstanding shares. Icagen confirms that it is conducting preliminary discussions with Pfizer regarding a potential transaction.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter